These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

216 related items for PubMed ID: 24461997

  • 1. Capecitabine plus irinotecan versus 5-FU/leucovorin plus irinotecan in the treatment of colorectal cancer: a meta-analysis.
    Guo Y, Shi M, Shen X, Yang C, Yang L, Zhang J.
    Clin Colorectal Cancer; 2014 Jun; 13(2):110-8. PubMed ID: 24461997
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and safety of bevacizumab-based combination regimens in patients with previously untreated metastatic colorectal cancer: final results from a randomised phase II study of bevacizumab plus 5-fluorouracil, leucovorin plus irinotecan versus bevacizumab plus capecitabine plus irinotecan (FNCLCC ACCORD 13/0503 study).
    Ducreux M, Adenis A, Pignon JP, François E, Chauffert B, Ichanté JL, Boucher E, Ychou M, Pierga JY, Montoto-Grillot C, Conroy T.
    Eur J Cancer; 2013 Apr; 49(6):1236-45. PubMed ID: 23352604
    [Abstract] [Full Text] [Related]

  • 3. Capecitabine plus Irinotecan (XELIRI regimen) compared to 5-FU/LV plus Irinotecan (FOLFIRI regimen) as neoadjuvant treatment for patients with unresectable liver-only metastases of metastatic colorectal cancer: a randomised prospective phase II trial.
    Skof E, Rebersek M, Hlebanja Z, Ocvirk J.
    BMC Cancer; 2009 Apr 22; 9():120. PubMed ID: 19386096
    [Abstract] [Full Text] [Related]

  • 4. Differences in efficacy and safety between capecitabine and infusional 5-fluorouracil when combined with irinotecan for the treatment of metastatic colorectal cancer.
    Montagnani F, Chiriatti A, Licitra S, Aliberti C, Fiorentini G.
    Clin Colorectal Cancer; 2010 Oct 22; 9(4):243-7. PubMed ID: 20920997
    [Abstract] [Full Text] [Related]

  • 5. Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial.
    Xu RH, Muro K, Morita S, Iwasa S, Han SW, Wang W, Kotaka M, Nakamura M, Ahn JB, Deng YH, Kato T, Cho SH, Ba Y, Matsuoka H, Lee KW, Zhang T, Yamada Y, Sakamoto J, Park YS, Kim TW.
    Lancet Oncol; 2018 May 22; 19(5):660-671. PubMed ID: 29555258
    [Abstract] [Full Text] [Related]

  • 6. XELIRI plus bevacizumab compared with FOLFIRI plus bevacizumab as first-line setting in patients with metastatic colorectal cancer: experiences at two-institutions.
    Uygun K, Bilici A, Kaya S, Oven Ustaalioglu BB, Yildiz R, Temiz S, Seker M, Aksu G, Cabuk D, Gumus M.
    Asian Pac J Cancer Prev; 2013 May 22; 14(4):2283-8. PubMed ID: 23725128
    [Abstract] [Full Text] [Related]

  • 7. Meta-analysis comparing the safety and efficacy of metastatic colorectal cancer treatment regimens, capecitabine plus irinotecan (CAPIRI) and 5-fluorouracil/leucovorin plus irinotecan (FOLFIRI).
    Ding HH, Wu WD, Jiang T, Cao J, Ji ZY, Jin JH, Wang JJ, Song WF, Wang LW.
    Tumour Biol; 2015 May 22; 36(5):3361-9. PubMed ID: 25534239
    [Abstract] [Full Text] [Related]

  • 8. Bevacizumab in first-line therapy of metastatic colorectal cancer: a retrospective comparison of FOLFIRI and XELIRI.
    Ocvirk J, Rebersek M, Boc M.
    Anticancer Res; 2011 May 22; 31(5):1777-82. PubMed ID: 21617239
    [Abstract] [Full Text] [Related]

  • 9. A randomised, double-blind, placebo-controlled multi-centre phase III trial of XELIRI/FOLFIRI plus simvastatin for patients with metastatic colorectal cancer.
    Lim SH, Kim TW, Hong YS, Han SW, Lee KH, Kang HJ, Hwang IG, Lee JY, Kim HS, Kim ST, Lee J, Park JO, Park SH, Park YS, Lim HY, Jung SH, Kang WK.
    Br J Cancer; 2015 Nov 17; 113(10):1421-6. PubMed ID: 26505681
    [Abstract] [Full Text] [Related]

  • 10. Comparing safety and efficacy of first-line irinotecan/fluoropyrimidine combinations in elderly versus nonelderly patients with metastatic colorectal cancer: findings from the bolus, infusional, or capecitabine with camptostar-celecoxib study.
    Jackson NA, Barrueco J, Soufi-Mahjoubi R, Marshall J, Mitchell E, Zhang X, Meyerhardt J.
    Cancer; 2009 Jun 15; 115(12):2617-29. PubMed ID: 19382200
    [Abstract] [Full Text] [Related]

  • 11. Capecitabine plus 3-weekly irinotecan (XELIRI regimen) as first-line chemotherapy for metastatic colorectal cancer: phase II trial results.
    Patt YZ, Lee FC, Liebmann JE, Diamandidis D, Eckhardt SG, Javle M, Justice GR, Keiser W, Salvatore JR, Bexon A, Lin E.
    Am J Clin Oncol; 2007 Aug 15; 30(4):350-7. PubMed ID: 17762434
    [Abstract] [Full Text] [Related]

  • 12. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study.
    Fuchs CS, Marshall J, Mitchell E, Wierzbicki R, Ganju V, Jeffery M, Schulz J, Richards D, Soufi-Mahjoubi R, Wang B, Barrueco J.
    J Clin Oncol; 2007 Oct 20; 25(30):4779-86. PubMed ID: 17947725
    [Abstract] [Full Text] [Related]

  • 13. A phase I/II study of biweekly capecitabine and irinotecan plus bevacizumab as second-line chemotherapy in patients with metastatic colorectal cancer.
    Suenaga M, Mizunuma N, Matsusaka S, Shinozaki E, Ozaka M, Ogura M, Chin K, Yamaguchi T.
    Drug Des Devel Ther; 2015 Oct 20; 9():1653-62. PubMed ID: 25834402
    [Abstract] [Full Text] [Related]

  • 14. Bevacizumab combined with chemotherapy in the second-line treatment of metastatic colorectal cancer: results from the phase II BEVACOLOR study.
    Bennouna J, Borg C, Delord JP, Husseini F, Trillet-Lenoir V, Faroux R, François E, Ychou M, Goldwasser F, Bouché O, Senellart H, Kraemer S, Douillard JY.
    Clin Colorectal Cancer; 2012 Mar 20; 11(1):38-44. PubMed ID: 21803002
    [Abstract] [Full Text] [Related]

  • 15. Cetuximab plus XELIRI or XELOX for first-line therapy of metastatic colorectal cancer.
    Moosmann N, Heinemann V.
    Clin Colorectal Cancer; 2008 Mar 20; 7(2):110-7. PubMed ID: 18501070
    [Abstract] [Full Text] [Related]

  • 16. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.
    Peeters M, Price TJ, Cervantes A, Sobrero AF, Ducreux M, Hotko Y, André T, Chan E, Lordick F, Punt CJ, Strickland AH, Wilson G, Ciuleanu TE, Roman L, Van Cutsem E, Tzekova V, Collins S, Oliner KS, Rong A, Gansert J.
    J Clin Oncol; 2010 Nov 01; 28(31):4706-13. PubMed ID: 20921462
    [Abstract] [Full Text] [Related]

  • 17. Study protocol of the Asian XELIRI ProjecT (AXEPT): a multinational, randomized, non-inferiority, phase III trial of second-line chemotherapy for metastatic colorectal cancer, comparing the efficacy and safety of XELIRI with or without bevacizumab versus FOLFIRI with or without bevacizumab.
    Kotaka M, Xu R, Muro K, Park YS, Morita S, Iwasa S, Uetake H, Nishina T, Nozawa H, Matsumoto H, Yamazaki K, Han SW, Wang W, Ahn JB, Deng Y, Cho SH, Ba Y, Lee KW, Zhang T, Satoh T, Buyse ME, Ryoo BY, Shen L, Sakamoto J, Kim TW.
    Chin J Cancer; 2016 Dec 22; 35(1):102. PubMed ID: 28007025
    [Abstract] [Full Text] [Related]

  • 18. Randomized phase II trial of TEGAFIRI (tegafur/uracil, oral leucovorin, irinotecan) compared with FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) in patients with unresectable/recurrent colorectal cancer.
    Shigeta K, Hasegawa H, Okabayashi K, Tsuruta M, Ishii Y, Endo T, Ochiai H, Kondo T, Kitagawa Y.
    Int J Cancer; 2016 Aug 15; 139(4):946-54. PubMed ID: 27061810
    [Abstract] [Full Text] [Related]

  • 19. Bevacizumab with FOLFIRI or XELIRI in the First-line Therapy of Metastatic Colorectal Carcinoma: Results from Czech Observational Registry.
    Kocakova I, Melichar B, Kocak I, Bortlicek Z, Büchler T, Dusek L, Petruzelka L, Kohoutek M, Prausová J, Finek J, Mohelnikova-Duchonova B, Vyzula R.
    Anticancer Res; 2015 Jun 15; 35(6):3455-61. PubMed ID: 26026110
    [Abstract] [Full Text] [Related]

  • 20. Bevacizumab in Combination with Capecitabine plus Irinotecan as First-Line Therapy in Metastatic Colorectal Cancer: A Pooled Analysis of 2 Phase II Trials.
    García Alfonso P, Muñoz Martin A, Alvarez Suarez S, Blanco Codeidido M, Mondejar Solis R, Tapia Rico G, López Martín P, Martin M.
    Onkologie; 2013 Jun 15; 36(6):363-7. PubMed ID: 23774151
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.